Staphylococcus aureus DNA-directed RNA polymerase (RNAP) (RNAP)

Staphylococcus aureus DNA-directed RNA polymerase (RNAP) is a complex, multi-subunit enzyme essential for bacterial survival, as it catalyzes the transcription of DNA into all types of RNA (UniProt, 2024). The core enzyme is composed of subunits alpha, beta, beta', and omega, which require a sigma factor for promoter recognition and initiation of transcription (PubMed, PMID: 25613620). This enzyme is a major target for antibacterial therapy, most notably by the rifamycin class of drugs, which bind to the beta subunit near the active site to physically block the elongation of the nascent RNA transcript (DrugBank, DB01045). In the context of Staphylococcus aureus, this target is particularly significant for treating methicillin-resistant S. aureus (MRSA) and biofilm-associated infections (PubMed, PMID: 30224514). However, the clinical utility of targeting this enzyme is often limited by the rapid emergence of resistance via single-point mutations in the rpoB gene (PubMed, PMID: 30224514). Additionally, drugs targeting this polymerase, such as rifampicin, are known to induce various cytochrome P450 enzymes, leading to significant drug-drug interactions (StatPearls, NBK557480). Despite these challenges, RNAP remains a cornerstone target in the development of new anti-staphylococcal agents due to its fundamental role in gene expression.

Other names

Staphylococcus aureus DNA-dependent RNA polymeraseRNA polymeraseRNAPTranscriptaseDNA-directed RNA polymerase

Inhibition of RNA synthesis by binding to the beta subunit of the RNA polymerase complex, thereby physically blocking the path of the nascent RNA transcript.